Rethinking the Science of COPD

We are working to transform the way COPD is understood and treated.

Our Latest Stories

Your Health

December 4, 2024

Early Detection and Diagnosis of Autoimmune Type 1 Diabetes – Alizée’s Story

/assets/dotcom/content-app/events/banner-investors-events_20230703194346.jpg

Third quarter 2024 results

Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session.

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

Igniting the Potential in Everyone

We’re proud to be premium partner of Paris 2024.

Science and sport aren’t that different. Just like athletes do, we overcome setbacks to keep moving forward, not just for ourselves, but for our patients, colleagues, families and friends.

About Us

Who We Are

We are an innovative global healthcare company.

Our Pipeline

5

Therapeutic areas

78

Compounds in clinical development

27

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases

December 7, 2024
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
December 6, 2024
Press Release: Availability of the profit and loss information of Sanofi excluding Opella
November 15, 2024
Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland
November 15, 2024
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria